Table 4 Adverse events reported in the included RCTs
From: Efficacy and safety of mycophenolate mofetil treatment in IgA nephropathy: a systematic review
Adverse events | Studies reporting (n) | MMF (n/n) | Control (n/n) | RR (95% CI) | P value |
|---|---|---|---|---|---|
Total patients with adverse events | 7 | 27/148 | 20/125 | 1.14 [0.67, 1.93] | 0.63 |
Specific adverse events | |||||
Infection | |||||
MMF vs Placebo (or Steroid) | 3 | 5/72 | 0/64 | 3.84 [0.61, 24.03] | 0.15 |
MMF vs other immunosuppressive agents | 2 | 4/61 | 5/60 | 0.77 [0.22, 2.71] | 0.68 |
Gastrointestinal disorders | |||||
MMF vs Placebo (or Steroid) | 3 | 7/72 | 0/64 | 5.02 [0.83, 30.15] | 0.08 |
MMF vs other immunosuppressive agents | 3 | 2/81 | 8/80 | 0.25 [0.05, 1.13] | 0.07 |
Abnormal liver function | |||||
MMF vs Placebo (or Steroid) | 0 | 0 | 0 | - | - |
MMF vs other immunosuppressive agents | 4 | 4/102 | 6/90 | 0.66 [0.18, 2.42] | 0.74 |
Abnormal blood counts | |||||
MMF vs Placebo (or Steroid) | 2 | 4/41 | 0/33 | 4.25 [0.46, 39.30] | 0.20 |
MMF vs other immunosuppressive agents | 3 | 3/82 | 5/70 | 0.53 [0.15, 1.94] | 0.34 |
Hair loss | |||||
MMF vs Placebo (or Steroid) | 0 | 0 | 0 | - | - |
MMF vs other immunosuppressive agents | 2 | 0/61 | 2/60 | 0.32 [0.03, 3.02] | 0.32 |
Irregular menstruation | |||||
MMF vs Placebo (or Steroid) | 0 | 0 | 0 | - | - |
MMF vs other immunosuppressive agents | 1 | 0/19 | 2/18 | 0.19 [0.01, 3.71] | 0.27 |